Bausch Health Canada receives a positive recommendation from the CADTH Canadian Drug Expert Committee for Duobrii - a novel topical anti-psoriatic prescription drug

10 November 2020 - Positive CADTH recommendation moves Duobrii closer to federal, provincial and territorial drug plan reimbursement. ...

Read more →

CADTH recommends new treatment option for patients with plaque psoriasis

30 October 2020 - The CADTH Canadian Drug Expert Committee has recommended that halobetasol (ulobetasol) propionate with tazarotene (Duobrii) be reimbursed ...

Read more →

CADTH publishes final recommendation for Blincyto

29 October 2020 - The pERC final recommendation is based on a reconsideration of the initial recommendation and feedback from eligible ...

Read more →

Nexplanon recommended after second submission

22 October 2020 - The first submission was withdrawn. ...

Read more →

CADTH in favour of new indication for Soliris

22 October 2020 - CADTH has finalised its assessment of eculizumab for adult patients with refractory generalised myasthenia gravis. ...

Read more →

Next-generation wet AMD therapy Beovu, now available in Canada, receives positive recommendation from CADTH Drug Expert Committee

5 October 2020 - Positive recommendation by CADTH speaks to evidence and clinical benefit of Beovu. ...

Read more →

CADTH publishes final outcome for new medicine for patients with acquired thrombotic thrombocytopenic purpura

1 September 2020 - The CADTH Canadian Drug Expert Committee has recommended that caplacizumab not be reimbursed for the treatment of ...

Read more →

CADTH publishes final recommendation on new indication for Soliris

24 August 2020 - The new indication is for the treatment of patients with neuromyelitis optica spectrum disorder. ...

Read more →

CADTH publishes final recommendation for a new combination product for HIV infection

24 July 2020 - Cabenuva (cabotegravir and rilpivirine extended release injectable suspensions) is indicated as a complete regimen for the treatment ...

Read more →

CADTH posts final recommendation for Aimovig

26 July 2020 - Final recommendation informed by input from Migraine Canada and Migraine Quebec. ...

Read more →

CADTH publishes final recommendation for Mayzent

23 July 2020 - The recommendation relates to the use of siponomid for the treatment of patients with secondary progressive multiple ...

Read more →

HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price

20 July 2020 - CADTH recommends Vascepa be reimbursed for patients with established cardiovascular disease under certain conditions. ...

Read more →

CADTH publishes final recommendation for Stelara

20 July 2020 - CADTH has completed its assessment of ustekinumab by intravenous injection for the treatment of adult patients ...

Read more →

Dupixent (dupilumab) receives positive recommendation from INESSS for the treatment of moderate to severe atopic dermatitis in adolescents

14 July 2020 - The Institut national d'excellence en santé et en services sociaux (INESSS) recommends extending existing coverage in Quebec ...

Read more →

CADTH publishes final recommendation for Crysvita

1 June 2020 - CADTH has completed its assessment of burosumab for the treatment of patients with X-linked hypophosphatemia. ...

Read more →